Designed immunocytokine reduces disease severity inside a mouse model of colitis
Designed immunocytokine reduces disease severity inside a mouse model of colitis. stimulating TRegexpansion, and exhibiting superior disease control Forsythoside A to the combined IL-2/JES61 complex inside a mouse colitis model. These studies provide an executive blueprint for resolving a major barrier to the implementation of functionally related IL-2/antibody complexes for treatment of human being disease. == Intro == Interleukin-2 (IL-2) is definitely a pleiotropic cytokine that orchestrates the proliferation, survival, and function of both immune effector cells and regulatory T (TReg) cells to keep up immune homeostasis. IL-2 signals through activation of either a high-affinity (~100 pM) heterotrimeric receptor (composed of IL-2 receptor- [IL-2R], IL-2R, and the shared common gamma [c]) or an intermediate-affinity (~1 nM) heterodimeric receptor (composed of only the IL-2R and cchains) (13). As a result, IL-2 sensitivity is definitely dictated from the non-signaling IL-2R chain, which is definitely abundantly indicated on the surface of TRegcells, but virtually absent from nave immune effector cells (i.e.natural killer [NK] cells and memory phenotype [MP] CD8+T cells) (1,2,4). Formation of the IL-2 cytokine-receptor complex prospects to activation of intracellular Janus kinase (JAK) proteins, which are Cish3 constitutively associated with IL-2R and c. JAK proteins phosphorylate important tyrosine residues in the receptor intracellular domains, leading to recruitment and activation of transmission transducer and activator of transcription (STAT)-5 to effect immune-related gene manifestation and regulate practical results (1,5,6). Due to its essential part in the differentiation and growth of TRegcells, the IL-2 cytokine has been extensively characterized in pre-clinical models to treat a range of autoimmune diseases, including diabetes and multiple sclerosis. These models have underlined the need to administer low doses of the cytokine to take advantage of the enhanced IL-2 sensitivity of TRegover effector cells (7,8). More recently, proof-of-concept clinical trials backed by mechanistic studies have exhibited that low-dose IL-2 therapy specifically activates and expands TRegcells to ameliorate autoimmune pathologies (911). However, careful dose titration is required for these studies and the off-target activation of effector cells (particularly activated cells with upregulated IL-2R expression) remains of concern. Boyman and colleagues demonstrated that treating mice with complexes of IL-2 with the anti-IL-2 antibody JES61 biases cytokine activity toward TRegcells to orchestrate Forsythoside A an immunosuppressive response (12), offering an exciting opportunity for targeted autoimmune disease therapy (13). Subsequent work has exhibited that IL-2/JES61 complexes prevent development of autoimmune diseases (1417) and promote graft tolerance (18,19) in mice. We recently decided the molecular structure of the IL-2/JES61 complex to elucidate the mechanistic basis for its selective stimulation of TRegover effector cells. JES61 sterically obstructs IL-2 conversation with the IL-2R and csubunits to block signaling on IL-2RLoweffector cells, but also undergoes a unique allosteric exchange mechanism with the IL-2R subunit, wherein surface-expressed IL-2R displaces the JES61 antibody and liberates Forsythoside A the cytokine to signal through the high-affinity heterotrimeric receptor on IL-2RHighTRegcells (Fig. 1a). This phenomenon occurs because key residues in the IL-2 AB interhelical loop engage the JES61 antibody and the IL-2R subunit in distinct orientations; thus, IL-2-antibody and IL-2-receptor binding Forsythoside A are mutually unique, leading to bidirectional exchange. Activation of the IL-2 signaling pathway on IL-2RHighcells further upregulates IL-2R expression to create a positive feedback loop that exquisitely favors TRegexpansion (17). == Physique 1. Unique antibody-receptor exchange mechanism underlies TRegbias of mixed IL-2/JES61 complex. == (a) Schematic of the mechanistic rationale for IL-2/JES61 complex-mediated selective potentiation of TRegcells. The JES61 antibody (shown in single-chain format) sterically obstructs IL-2 engagement of the IL-2R and csubunits, preventing activation of IL-2RLoweffector cells (left). However, allosteric exchange between JES61 and the IL-2R subunit allows for unique signaling on IL-2RHighTRegs, biasing toward an immunosuppressive response (right).(b)IL-2 was immobilized and 500 nM IL-2R (top) or 500 nM JES61 antibody (bottom) was injected at time 0 min. After 10 minutes, various concentrations of JES61 antibody ranging from 31 nM to 2 M (top) or various concentrations of IL-2R ranging from 0.5 M to 32 M (bottom) were added and second-harmonic generation signal change (SHG) was monitored. Exchange schemes are shown atleft.(c)Molecular structure of the IL-2 cytokine bound to JES61 (PDB ID 4YQX) (17) overlaid with the IL-2R subunit from the IL-2 cytokine-receptor quaternary complex structure (PDB ID 2B5I) (3), highlighting the AB (red), BC (orange), and CD (green) interhelical loops of the cytokine (top). Molecular dynamics simulations of free IL-2 were conducted starting from the cytokines conformations in the.